Covid-19 test maker E25Bio Inc. was hit with a consumer suit claiming its at-home rapid tests are “worthless and inaccurate” and not approved by the Food and Drug Administration, according to a federal proposed class action filed Friday in Manhattan.
The lawsuit comes two weeks after the FDA warned consumers to avoid using these tests and the same day the company announced a formal recall. The lawsuit, filed in the U.S. District Court for the Southern District of New York, claims fraud and violation of New York business law on behalf of proposed classes of E25Bio Covid test purchasers ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.